Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: an [11C]ABP688 and PET imaging study in depression - Esterlis, I; DellaGioia, N; Pietrzak, R H; Matuskey, D; Nabulsi, N; Abdallah, C G; Yang, J; Pittenger, C; Sanacora, G; Krystal, J H; Parsey, R V; Carson, R E; et al. (Molecular psychiatry, 2018)
Keywords: 631/337; 631/378; Adult; Antidepressants; Antidepressive Agents - pharmacology; Anxiety disorders; Behavioral Sciences; Biological Psychology; Biomedical engineering; Brain - metabolism; Carbon Radioisotopes; Case-Control Studies; Comparative analysis; Depression - diagnostic imaging; Depressive Disorder, Major - diagnostic imaging; Depressive Disorder, Major - metabolism; Dosage and administration; Drug abuse; Excitatory Amino Acid Antagonists - pharmacology; Female; Glutamatergic transmission; Glutamic Acid - metabolism; Glutamic acid receptors (metabotropic); Health care; Humans; Internalization; Intravenous administration; Ketamine; Ketamine - metabolism; Ketamine - pharmacology; Ligands; Major depressive disorder; Male; Medicine; Medicine & Public Health; Mental depression; Mental disorders; Metabotropic glutamate receptors; Metabotropic receptors; N-Methyl-D-aspartic acid receptors; Neurosciences; original-article; Pharmacotherapy; Positron emission tomography; Positron-Emission Tomography - methods; Proteins; Psychiatry; Radiation; Receptor, Metabotropic Glutamate 5 - drug effects; Receptor, Metabotropic Glutamate 5 - metabolism; Spectrum analysis; Substance abuse treatment; Tomography